Back to Search Start Over

Polymorphism in ASCL1 target gene DDC is associated with clinical outcomes of small cell lung cancer patients

Authors :
Ji Hyun Kim
Shin Yup Lee
Jin Eun Choi
Sook Kyung Do
Jang Hyuck Lee
Mi Jeong Hong
Hyo‐Gyoung Kang
Won Kee Lee
Kyung Min Shin
Ji Yun Jeong
Sun Ha Choi
Yong Hoon Lee
Hyewon Seo
Seung Soo Yoo
Jaehee Lee
Seung Ick Cha
Chang Ho Kim
Jae Yong Park
Source :
Thoracic Cancer, Vol 11, Iss 1, Pp 19-28 (2020)
Publication Year :
2020
Publisher :
Wiley, 2020.

Abstract

Background Achaete‐scute homolog 1 (ASCL1) is a basic helix‐loop‐helix transcription factor and is essential in the differentiation of neuroendocrine cells and neural tissues. ASCL1 is frequently overexpressed in small cell lung cancer (SCLC) and plays a crucial role in the pathogenesis of SCLC. Methods This study was conducted to identify the association between single nucleotide polymorphisms (SNPs) in ASCL1 target genes and clinical outcomes of patients with SCLC after chemotherapy. A total of 261 patients diagnosed with SCLC were enrolled in this study. The association between 103 SNPs in 58 ASCL1 target genes and the response to chemotherapy and survival of patients with SCLC were analyzed. Results Among the 103 SNPs, 10 SNPs were significantly associated with the response to chemotherapy, and 19 SNPs were associated with OS in multivariate analyses. Among these, Dopa Decarboxylase (DDC) rs12666409A>T was significantly associated with both a worse response to chemotherapy and worse OS (adjusted odds ratio [aOR] = 0.40, 95% CI = 0.18–0.90, P = 0.03; adjusted hazard ratio [aHR] = 1.52, 95% CI = 1.10–2.10, P = 0.01, respectively, under a dominant model). In a stage‐stratified analysis, the association was significant only in the extensive disease subgroup (aOR = 0.19, 95% CI = 0.06–0.60, P = 0.01; aHR = 1.73, 95% CI = 1.16–2.56, P = 0.01, respectively, under a dominant model), but not in the limited disease subgroup. Conclusion The results of our study suggest that DDC rs12666409A>T may be useful markers for predicting the clinical outcomes of patients with SCLC undergoing chemotherapy.

Details

Language :
English
ISSN :
17597714, 17597706, and 60013044
Volume :
11
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Thoracic Cancer
Publication Type :
Academic Journal
Accession number :
edsdoj.f844a60013044e5b1b770884dce9ed0
Document Type :
article
Full Text :
https://doi.org/10.1111/1759-7714.13212